4//SEC Filing
BARR PHARMACEUTICALS INC 4
Accession 0001209191-08-067454
CIK 0000010081operating
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 12:18 PM ET
Size
27.9 KB
Accession
0001209191-08-067454
Insider Transaction Report
Form 4
MCKEE WILLIAM
Sr.VP, CFO & Treasurer
Transactions
- Disposition to Issuer
Common Stock
2008-12-23−8,977→ 0 total - Disposition to Issuer
Stock Options
2008-12-23−3,528→ 0 totalExercise: $26.58Exp: 2012-08-07→ Common Stock (3,528 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−75,000→ 0 totalExercise: $49.22From: 2008-11-11Exp: 2018-03-04→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Options
2008-12-23−45,000→ 0 totalExercise: $43.34Exp: 2013-07-30→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−30,000→ 0 totalExercise: $46.99Exp: 2015-07-27→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−15,000→ 0 totalExercise: $49.49From: 2008-11-11Exp: 2017-03-07→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Options
2008-12-23−78,749→ 0 totalExercise: $36.33Exp: 2011-08-08→ Common Stock (78,749 underlying) - Disposition to Issuer
Stock Options
2008-12-23−30,000→ 0 totalExercise: $35.01Exp: 2014-08-04→ Common Stock (30,000 underlying)
Footnotes (11)
- [F1]Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 5,630 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $358,182.
- [F10]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $320,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $55.81 per share.
- [F11]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,296,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share.
- [F2]Option vested equally over a 3 year period from grant date
- [F3]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $2,376,117.20, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $36.3267 per share.
- [F4]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $140,837.76, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $26.58 per share.
- [F5]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,042,200, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share.
- [F6]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $944,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share.
- [F7]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $585,300, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share.
- [F8]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $531,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share.
- [F9]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $255,150, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share.
Documents
Issuer
BARR PHARMACEUTICALS INC
CIK 0000010081
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000010081
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 12:18 PM ET
- Size
- 27.9 KB